Indonesia Cancer & Tumor Statistics: 2026 Policy Update

Why this report matters

The latest public health projections for 2026 outline a substantial and shifting burden of cancer and tumor pathologies in Indonesia. The projected prevalence creates resource, economic, and system-level pressure across Indonesian healthcare.

Clear terminology, prevention, early detection, and access to appropriate care help the public ask better questions and help health systems plan where education and services are needed.

Tumor versus cancer

A tumor is an abnormal growth or mass of tissue and may be benign or malignant. Cancer is malignant disease that can invade nearby tissue and may spread to distant organs. The distinction matters because the diagnostic pathway, treatment, and follow-up can be very different.

National epidemiological profile

The projections distinguish incidence, or new diagnoses, from mortality, or deaths. Breast and cervical cancers lead projected incidence, while lung and liver cancers contribute heavily to projected mortality. Different patterns require disease-specific prevention, detection, diagnostic, and treatment strategies.

• Breast cancer: 73,572 projected new cases and 8,627 deaths.
• Cervical cancer: 36,633 projected new cases and 8,028 deaths.
• Lung cancer: 33,712 projected new cases and 18,771 deaths.
• Colorectal cancer: 20,615 projected new cases and 11,696 deaths.
• Liver cancer: 20,074 projected new cases and 13,528 deaths.

Factors behind the increasing burden

• Population aging and longer exposure to accumulated cellular damage.
• Smoking, diet, physical inactivity, obesity, and other behavioral factors.
• Oncogenic infections, including HPV and hepatitis B.
• Environmental and occupational exposure.
• Genetic predisposition, diagnostic gaps, and delayed access to specialist assessment.

Prevention and early detection priorities

Prevention priorities include tobacco control, limiting alcohol, healthy nutrition, physical activity, HPV and hepatitis B vaccination, and access to evidence-based screening. Screening recommendations vary by age, risk, sex, and clinical context; individual decisions should be discussed with a qualified healthcare professional.

• Pay attention to persistent, worsening, or unusual bodily changes.
• Use recommended vaccination and screening programs when eligible.
• Seek professional assessment for a new or changing lump, unexplained bleeding, persistent symptoms, or concerning test results.
• Do not use public education as a substitute for individual diagnosis or treatment.